<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:34:45Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7400216" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7400216</identifier>
        <datestamp>2020-08-13</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Intern Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Intern Med</journal-id>
              <journal-id journal-id-type="pmc">JAMA Intern Med</journal-id>
              <journal-title-group>
                <journal-title>JAMA Internal Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2168-6106</issn>
              <issn pub-type="epub">2168-6114</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7400216</article-id>
              <article-id pub-id-type="pmcid">PMC7400216</article-id>
              <article-id pub-id-type="pmc-uid">7400216</article-id>
              <article-id pub-id-type="pmid">32744599</article-id>
              <article-id pub-id-type="doi">10.1001/jamainternmed.2020.2993</article-id>
              <article-id pub-id-type="publisher-id">ioi200046</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="domain" specific-use="print">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-first">
                  <subject>Online First</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women</article-title>
                <subtitle>A Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women</alt-title>
                <alt-title alt-title-type="running-head">Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Dumoulin</surname>
                    <given-names>Chantale</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="ioi200046aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morin</surname>
                    <given-names>Mélanie</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="ioi200046aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Danieli</surname>
                    <given-names>Coraline</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="ioi200046aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cacciari</surname>
                    <given-names>Licia</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="ioi200046aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mayrand</surname>
                    <given-names>Marie-Hélène</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="ioi200046aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tousignant</surname>
                    <given-names>Michel</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="ioi200046aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Abrahamowicz</surname>
                    <given-names>Michal</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="ioi200046aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <on-behalf-of>for the Urinary Incontinence and Aging Study Group</on-behalf-of>
              </contrib-group>
              <aff id="ioi200046aff1"><label>1</label>School of Rehabilitation, Faculty of Medicine, Université de Montréal and Research Center of the Institut Universitaire de Gériatrie de Montréal, Montréal, Québec, Canada</aff>
              <aff id="ioi200046aff2"><label>2</label>School of Rehabilitation, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Research Center of the Centre Hospitalier de l’Université de Sherbrooke, Sherbrooke, Québec, Canada</aff>
              <aff id="ioi200046aff3"><label>3</label>Research Institute of the McGill University Health Center, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada</aff>
              <aff id="ioi200046aff4"><label>4</label>Department of Obstetrics and Gynecology and Social and Preventive Medicine, Université de Montréal, Research Center of the Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada</aff>
              <aff id="ioi200046aff5"><label>5</label>Department of Epidemiology, Biostatistics, and Occupational Health, McGill University and Research Institute of the McGill University Health Center, Montreal, Québec, Canada</aff>
              <author-notes>
                <title>Article Information</title>
                <p content-type="byline-footnote" specific-use="print"><bold>Group Information:</bold> Urinary Incontinence and Aging Study Group members appear at the end of the article.</p>
                <p><bold>Accepted for Publication:</bold> June 1, 2020.</p>
                <p content-type="published-online"><bold>Published Online:</bold> August 3, 2020. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamainternmed.2020.2993</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://jamanetwork.com/journals/jamainternalmedicine/pages/instructions-for-authors#SecOpenAccess">CC-BY License</ext-link>. © 2020 Dumoulin C et al. <italic>JAMA Internal Medicine</italic>.</p>
                <corresp id="ioi200046cor1"><bold>Corresponding Author:</bold> Chantale Dumoulin, PhD, School of Rehabilitation, Faculty of Medicine, Université de Montréal, 4565, Chemin Queen-Mary, Montréal, QC H3W 1W5, Canada (<email xlink:href="chantal.dumoulin@umontreal.ca">chantal.dumoulin@umontreal.ca</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Dumoulin and Abrahamowicz had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Dumoulin, Morin, Mayrand, Tousignant, Abrahamowicz.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p>
                <p><italic>Drafting of the manuscript:</italic> Dumoulin, Morin, Tousignant.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> All authors.</p>
                <p><italic>Statistical analysis:</italic> Dumoulin, Danieli, Cacciari, Abrahamowicz.</p>
                <p><italic>Obtained funding:</italic> Dumoulin, Morin, Mayrand.</p>
                <p><italic>Administrative, technical, or material support:</italic> Dumoulin, Morin.</p>
                <p><italic>Supervision:</italic> Dumoulin, Morin, Cacciari, Mayrand, Abrahamowicz.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Dumoulin reported receiving grants from Canadian Institutes of Health Research, the Canadian Foundation on Innovation, and the Canadian Research Chair during the conduct of the study. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by the Canadian Institutes of Health Research (grant MSH-258993) and statistical analyses were partly supported by the Canadian Institutes of Health Research (grant PJT-148946). Dr Dumoulin received a salary award from the Canadian Research Chair Tier II program. Drs Morin and Mayrand received salary awards from the Fonds de la Recherche du Québec–Santé. The laboratory infrastructures were funded by the Canadian Foundation for Innovation.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The study funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</p>
                <p content-type="study-group-members-end"><bold>Group Information:</bold> Members of the Urinary Incontinence and Aging Study Group: Dr Marie-Claude Lemieux (Maisonneuve Rosemont Hospital), Dr Barabara Reichetzer, Dr Laurence Simard Emond, and Dr Nathalie Leroux (Université de Montréal and Centre Hospitalier de l’Université de Montréal), Dr Eric Walter (McGill University), and Dr Isabelle Girard and Dr Le Mai Tu (Université de Sherbrooke and Centre Hospitalier de l’Université de Sherbrooke).</p>
                <p><bold>Additional Contributions:</bold> Francine Giroux, MSc (Research Center of the Institut Universitaire de Gériatrie de Montréal), was the statistician responsible for randomization. Yvonne Ruella, MSc (Research Center of the Institut Universitaire de Gériatrie de Montréal), and Marie-Soleil Caroll, MSc (Research Center of the Centre Hospitalier de l’Université de Sherbrooke), served as study coordinators. There was no compensation outside salary. We thank data assessors and analysts, physical therapists involved in treatments and assessments, and study participants for their support and dedication to this research project.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 3</xref>.</p>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>10</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2020-08-03T10:00">
                <day>3</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>3</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
              <volume>180</volume>
              <issue>10</issue>
              <fpage>1284</fpage>
              <lpage>1293</lpage>
              <history>
                <date date-type="received">
                  <day>2</day>
                  <month>4</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>1</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2020 Dumoulin C et al. <italic>JAMA Internal Medicine</italic>.</copyright-statement>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamainternmed-e202993.pdf">jamainternmed-e202993.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archinte/fullarticle/10.1001/jamainternmed.2020.2993"/>
              <related-article related-article-type="commentary" id="d38e292" ext-link-type="doi" xlink:href="10.1001/jamainternmed.2020.2983"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-ioi200046-1">
                  <title>Question</title>
                  <p>Is pelvic floor muscle training (PFMT) delivered in a group setting noninferior to the recommended individual PFMT for urinary incontinence in older women (aged ≥60 years)?</p>
                </sec>
                <sec id="ab-ioi200046-2">
                  <title>Findings</title>
                  <p>In this noninferiority randomized clinical trial of 362 older women with urinary incontinence, the median percentage reduction in incontinence episodes at 1 year was 70% in individual compared with 74% in group-based PFMT intervention. The difference between groups fell below the noninferiority margin of 10%, supporting noninferiority of group-based PFMT.</p>
                </sec>
                <sec id="ab-ioi200046-3">
                  <title>Meaning</title>
                  <p>The findings of this trial show that group-based PFMT is noninferior to the recommended individual PFMT; widespread use in clinical practice could increase urinary incontinence treatment capacity for older women.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-ioi200046-4">
                  <title>Importance</title>
                  <p>Urinary incontinence is one of the most prevalent health concerns experienced by older women (aged ≥60 years). Individual pelvic floor muscle training (PFMT) is the recommended first-line treatment for stress or mixed urinary incontinence in women, but human and financial resources limit its delivery. Whether group-based PFMT performs as well as individual PFMT in this population remains unclear.</p>
                </sec>
                <sec id="ab-ioi200046-5">
                  <title>Objective</title>
                  <p>To assess the efficacy of group-based PFMT relative to individual PFMT for urinary incontinence in older women.</p>
                </sec>
                <sec id="ab-ioi200046-6">
                  <title>Design, Setting, and Participants</title>
                  <p>The Group Rehabilitation or Individual Physiotherapy (GROUP) study is a single-blind, randomized, noninferiority trial conducted in 2 Canadian research centers, from July 1, 2012, to June 2, 2018. A total of 362 community-dwelling women aged 60 years or older with symptoms of stress or mixed urinary incontinence were enrolled.</p>
                </sec>
                <sec id="ab-ioi200046-7">
                  <title>Interventions</title>
                  <p>After an individual session conducted to learn how to contract pelvic floor muscles, participants completed 12-week PFMT as part of a group of 8 women (n = 178) or in individual sessions (n = 184).</p>
                </sec>
                <sec id="ab-ioi200046-8">
                  <title>Main Outcomes and Measures</title>
                  <p>The primary outcome measure was the percentage reduction in urinary incontinence episodes at 1 year, as reported in a 7-day bladder diary and relative to pretreatment baseline. Secondary outcomes included lower urinary tract–related signs, symptoms, and quality of life immediately following treatment and at 1 year. Per-protocol analysis was used.</p>
                </sec>
                <sec id="ab-ioi200046-9">
                  <title>Results</title>
                  <p>Among 362 women who were randomized (mean [SD] age, 67.9 [5.8] years), 319 women (88%) completed the 1-year follow-up and were included in the per-protocol analysis. Median percentage reduction in urinary incontinence episodes was 70% (95% CI, 44%-89%) in individual PFMT compared with 74% (95% CI, 46%-86%) in group-based PFMT. The upper boundary of the 95% CI for the difference in the percentage reduction in urinary incontinence episodes at 1 year was lower than the prespecified margin for noninferiority of 10% (difference, 4%; 95% CI, −10% to 7%; <italic>P</italic> = .58), confirming noninferiority. Individual PFMT and group-based PFMT had similar effectiveness for all secondary outcomes at 1 year. Adverse events were minor and uncommon.</p>
                </sec>
                <sec id="ab-ioi200046-10">
                  <title>Conclusions and Relevance</title>
                  <p>Results of the GROUP study suggest that group-based PFMT is not inferior to the recommended individual PFMT for the treatment of stress and mixed urinary incontinence in older women. Widespread use in clinical practice may help increase continence-care affordability and treatment availability.</p>
                </sec>
                <sec id="ab-ioi200046-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02039830">NCT02039830</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser">
                <p>This randomized clinical trial demonstrates that outcomes of women participating in group-based pelvic floor muscle training are not inferior to outcomes of women receiving individualized training.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-IOI200046">
              <title>Introduction</title>
              <p>Urinary incontinence is one of the most prevalent health concerns confronting older women (aged ≥60 years).<sup><xref rid="ioi200046r1" ref-type="bibr">1</xref>,<xref rid="ioi200046r2" ref-type="bibr">2</xref></sup> A medical and social problem, urinary incontinence shame and negative self-perception may lead to reduced social interaction and physical activity, interfering with healthy aging.<sup><xref rid="ioi200046r3" ref-type="bibr">3</xref>,<xref rid="ioi200046r4" ref-type="bibr">4</xref>,<xref rid="ioi200046r5" ref-type="bibr">5</xref>,<xref rid="ioi200046r6" ref-type="bibr">6</xref></sup> Pelvic floor muscle training (PFMT) has been reported to be effective to cure or improve urinary incontinence symptoms in young, middle-aged, and older women with stress or mixed urinary incontinence.<sup><xref rid="ioi200046r7" ref-type="bibr">7</xref></sup> National and international clinical practice guidelines recommend supervised individual PFMT as first-line treatment for women with stress or mixed urinary incontinence.<sup><xref rid="ioi200046r8" ref-type="bibr">8</xref>,<xref rid="ioi200046r9" ref-type="bibr">9</xref></sup> However, inadequate human and financial resources limit the delivery of PFMT.<sup><xref rid="ioi200046r10" ref-type="bibr">10</xref></sup> Consequently, and frequently, surgery is used as first-line therapy despite serious adverse effects,<sup><xref rid="ioi200046r5" ref-type="bibr">5</xref>,<xref rid="ioi200046r11" ref-type="bibr">11</xref></sup> adding costs and pressure to the health care system. Pelvic floor muscle training delivered to a group of women rather than individually could overcome financial and human resource barriers.<sup><xref rid="ioi200046r12" ref-type="bibr">12</xref></sup> Group interventions are considered to be useful tools to promote behavior modification in the health promotion field, fostering peer support and discussion while increasing motivation by reducing stigma and isolation.<sup><xref rid="ioi200046r12" ref-type="bibr">12</xref></sup> Addressing urinary incontinence through group sessions could prove to be an effective means of encouraging active self-management, which is needed for long-term benefits. However, it is unclear whether group-based PFMT performs at least as well as the standard of care (individual PFMT), based on limited evidence.<sup><xref rid="ioi200046r8" ref-type="bibr">8</xref></sup></p>
              <p>We conducted the Group Rehabilitation or Individual Physiotherapy (GROUP) study to determine whether the effectiveness of group-based PFMT is not inferior to individual PFMT in women aged 60 years or older with stress or mixed urinary incontinence.</p>
            </sec>
            <sec id="H1-2-IOI200046">
              <title>Methods</title>
              <sec id="H2-1-IOI200046">
                <title>Design</title>
                <p>The GROUP study was designed as a single-blind, randomized, multicenter, noninferiority trial, with the primary objective of evaluating whether group-based PFMT was not inferior to individual PFMT for percentage reduction in urinary incontinence episodes 1-year postrandomization. Secondary objectives compared the 2 interventions immediately following treatment and at 1 year for the following variables: lower urinary tract–related signs, symptoms, and quality of life (QoL); urinary incontinence and PFMT self-efficacy; impression of improvement; satisfaction with treatment; and adverse events. Details of the study design were previously published<sup><xref rid="ioi200046r13" ref-type="bibr">13</xref></sup> and the study protocol is available in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 1</xref>. The study protocol was approved by the research ethics boards at both research centers of the Institut Universitaire de Gériatrie de Montréal and the Centre Hospitalier Universitaire de Sherbrooke. The GROUP trial was conducted as per the original protocol, with adjustments explained in the Statistical Analysis section. Participants provided written informed consent; participants did not receive financial compensation.</p>
                <p>The study was conducted from July 1, 2012, to June 2, 2018. Women were recruited from August 1, 2012, to May 1, 2017, through advertisements in community centers, newspapers, web and social media platforms, public conferences, a research bank of participants, and gynecology and urology clinics in the metropolitan areas of the 2 study centers (Montreal and Sherbrooke, Canada). Women were prescreened by telephone, and those meeting the inclusion criteria underwent subsequent on-site screening. Eligible participants were women aged 60 years or older with symptoms of stress or mixed urinary incontinence who reported at least 3 episodes of involuntary urine loss per week during the preceding 3 months.<sup><xref rid="ioi200046r14" ref-type="bibr">14</xref></sup> Stress and mixed urinary incontinence were confirmed using the validated Questionnaire for Incontinence Diagnosis.<sup><xref rid="ioi200046r15" ref-type="bibr">15</xref></sup> Exclusion criteria were body mass index (BMI) 35 or greater (calculated as weight in kilograms divided by height in meters squared), reduced mobility (requiring a mobility aid), chronic constipation,<sup><xref rid="ioi200046r16" ref-type="bibr">16</xref></sup> important pelvic organ prolapse (Pelvic Organ Prolapse Quantification System &gt;stage 2),<sup><xref rid="ioi200046r17" ref-type="bibr">17</xref></sup> physiotherapy treatment or surgery for urinary incontinence or pelvic organ prolapse in the past year, use of medications for urinary incontinence or affecting skeletal muscles, change in hormonal replacement therapy in the past 6 months, any leakage of stool or mucus, active urinary or vaginal infection in the past 3 months, or any comorbidities or risk factors interfering with the study.<sup><xref rid="ioi200046r13" ref-type="bibr">13</xref></sup></p>
                <p>Participants’ randomization was stratified by center (Montreal and Sherbrooke) and by urinary incontinence type (stress and mixed) within each center. Before the trial, an independent statistician provided a computer-generated list for each of the 4 resulting strata (center by type of urinary incontinence) to create random permutated blocks of varying sizes (4-6). The randomization process took place after the participant’s initial evaluation and written consent. Concealed randomization lists were used by an independent individual to assign eligible participants to 1 of the 2 trial arms (1:1). Research assistants (1 in each center) contacted the independent party to obtain the next sequential randomization and informed participants of their treatment randomization. Study investigators and physiotherapists assessing outcomes were not involved in treatment and remained blinded to the participants’ intervention randomization. Participants were asked not to discuss their intervention with the outcome assessor.</p>
                <p>After an individual session with a physiotherapist to learn how to effectively contract the pelvic floor muscle (PFM), women in both treatment arms received a 12-week PFMT program under the direction of an experienced pelvic floor physiotherapist, either in individual or group sessions. For both interventions, each weekly session lasted 1 hour and included a 15-minute educational period and a 45-minute exercise component. The exercise targeted PFM strength, power, endurance, coordination, and integration into daily living activities, such as coughing. The 12-week training protocol comprised three 4-week phases with the gradual addition of increasingly difficult exercises in terms of duration, number of repetitions, and position.<sup><xref rid="ioi200046r13" ref-type="bibr">13</xref></sup> The complete PFMT program is presented in eTable 1 and eTable 2 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>.</p>
                <p>In addition to the standard protocol, participants in the group-based PFMT arm who reported having difficulty with the PFM exercises were offered short private sessions with the physiotherapist to ensure understanding and correct performance of a PFM contraction. Furthermore, as per standard practice, participants in the individual PFMT arm used intravaginal electromyographic biofeedback during each treatment session for 10 to 15 minutes.</p>
                <p>Women in both study arms were expected to perform PFM exercises at home, 5 days per week during the 12-week physiotherapy program, and subsequently 3 days per week for 9 months. Attendance at PFMT sessions was monitored by the treating physiotherapists. Adherence to the home exercise program was assessed through participants’ exercise diaries during the 12-week intervention and then by telephone follow-ups at 6, 9, and 12 months. Participants were asked to refrain from seeking other forms of treatment during the study period (ie, until after the 1-year assessment).<sup><xref rid="ioi200046r13" ref-type="bibr">13</xref></sup></p>
                <p>Measurements were taken before the intervention, immediately after the 12-week PFMT period, and 1 year postrandomization. The primary outcome measure was the percentage reduction in the number of urinary incontinence episodes at 1 year reported in a 7-day bladder diary relative to the pretreatment baseline.<sup><xref rid="ioi200046r18" ref-type="bibr">18</xref></sup> Secondary outcomes, assessed in exploratory analyses after the 12-week intervention and at 1 year, included (1) number of daily urinary leakages,<sup><xref rid="ioi200046r18" ref-type="bibr">18</xref></sup> (2) number of micturitions per day and night recorded in the 7-day bladder diary,<sup><xref rid="ioi200046r18" ref-type="bibr">18</xref></sup> (3) amount of leakage on the 24-hour pad test,<sup><xref rid="ioi200046r19" ref-type="bibr">19</xref></sup> (4) 5 International Consultation on Incontinence Questionnaire (ICIQ) modules on urinary incontinence–related symptoms and QoL<sup><xref rid="ioi200046r20" ref-type="bibr">20</xref>,<xref rid="ioi200046r21" ref-type="bibr">21</xref></sup> (ICIQ-Urinary Incontinence Short Form, ICIQ-Nocturia, ICIQ-Vaginal Symptoms, ICIQ-Female Lower Urinary Tract Symptoms Sex, and ICIQ-Lower Urinary Tract Symptoms Quality of Life), (5) Geriatric Self-Efficacy Index,<sup><xref rid="ioi200046r22" ref-type="bibr">22</xref></sup> (6) Patient Global Impression of Improvement questionnaire,<sup><xref rid="ioi200046r23" ref-type="bibr">23</xref></sup> and (7) satisfaction with treatment.<sup><xref rid="ioi200046r24" ref-type="bibr">24</xref></sup> Pelvic floor muscle morphometry and function, PFMT-specific self-efficacy, detailed adherence data, and intervention costs were obtained and will be presented elsewhere.</p>
                <p>At 1 year, the proportion of participants reaching a minimal clinically important difference for key urinary incontinence–specific outcomes was compared. In addition, the effectiveness of both interventions was compared in subgroups of interest: center, urinary incontinence type, urinary incontinence severity, age, and BMI. Complications and adverse effects were recorded during the intervention, immediately posttreatment, and at 1 year.</p>
                <p>Sample size calculations followed the Consolidated Standards of Reporting Trials (<ext-link ext-link-type="uri" xlink:href="https://www.equator-network.org/reporting-guidelines/consort/">CONSORT</ext-link>) guidelines for randomized noninferiority clinical trials.<sup><xref rid="ioi200046r25" ref-type="bibr">25</xref></sup> The margin of noninferiority was set at a maximum 10% difference between average percentage reductions in urinary incontinence episodes in the individual minus the group-based intervention arms.<sup><xref rid="ioi200046r26" ref-type="bibr">26</xref>,<xref rid="ioi200046r27" ref-type="bibr">27</xref></sup> Accordingly, we calculated the sample size necessary to ensure 90% power for the 95% CI for the intervention effect to exclude a difference higher than 10% when assuming that the true effectiveness of the 2 interventions was equal.<sup><xref rid="ioi200046r25" ref-type="bibr">25</xref></sup> Based on prior evidence, we assumed a within-group SD of the individual PFMT percentage reduction in urinary incontinence episodes scores of 27%.<sup><xref rid="ioi200046r14" ref-type="bibr">14</xref>,<xref rid="ioi200046r28" ref-type="bibr">28</xref></sup> Under these assumptions, accounting for up to 15% attrition rate at 1 year, calculations using the PASS program for noninferiority trials<sup><xref rid="ioi200046r29" ref-type="bibr">29</xref></sup> indicated the need to randomize 182 participants per trial arm.</p>
              </sec>
              <sec id="H2-2-IOI200046">
                <title>Statistical Analysis</title>
                <p>Baseline characteristics of the treatment arms were summarized with descriptive statistics. Following CONSORT guidelines for noninferiority trials, main analyses used a per-protocol approach.<sup><xref rid="ioi200046r25" ref-type="bibr">25</xref></sup> In line with the International Consultation on Incontinence recommendations for pelvic floor physiotherapy research,<sup><xref rid="ioi200046r8" ref-type="bibr">8</xref></sup> we focused on outcomes at 1 year.<sup><xref rid="ioi200046r13" ref-type="bibr">13</xref></sup> Therefore, per-protocol analyses were limited to women who completed the 1-year assessment. As recommended, in sensitivity analyses we used the intention-to-treat (ITT) approach<sup><xref rid="ioi200046r25" ref-type="bibr">25</xref></sup> and used the same methods to analyze data on all initially randomized participants, with the last observation carried forward for those who did not complete the 1-year assessments.</p>
                <p>Initially, we planned to test the noninferiority hypothesis using the parametric, univariate, independent-sample <italic>t</italic> test to compare the mean outcomes in the 2 trial arms at 1 year and multivariable linear regression models if potential confounders were imbalanced.<sup><xref rid="ioi200046r13" ref-type="bibr">13</xref></sup> However, the observed values of the primary outcome (percent reduction in urinary incontinence episodes) had irregular and skewed distributions and diverged substantially from the classic normal distribution assumed when applying <italic>t</italic> tests and linear regression. Thus, these parametric analyses would be inappropriate for our data, with group-specific means affected by extreme values, resulting in inaccurate 95% CIs and <italic>P</italic> values. Therefore, our primary analyses relied on the nonparametric Wilcoxon rank sum test that compared the median outcome values in the 2 arms and avoided the normality assumption. Accordingly, as recommended for noninferiority trials, the hypothesis of noninferiority was to be accepted if the upper bound of the 2-tailed 95% CI (implying a conservative type I error of 0.025) for the median difference in percentage reduction of urinary incontinence episodes, estimated using a nonparametric bootstrap approach based on 300 resamples, excludes the noninferiority threshold.<sup><xref rid="ioi200046r25" ref-type="bibr">25</xref></sup> In addition, mean values and corresponding <italic>t</italic> test results are reported to assess whether the general pattern of results and final conclusions were consistent between nonparametric and parametric analyses, which addresses statistical significance or nonsignificance of the differences between the 2 trial arms.</p>
                <p>We used a multivariable logistic model to compare the odds of achieving a 50% or greater reduction in urinary incontinence episodes at 1 year between group-based and individual PFMT for all participants and for predefined strata based on center, urinary incontinence type, urinary incontinence severity, age, and BMI. Two-way interactions of these stratification variables with the randomization group were tested to verify whether the intervention effect varied across the corresponding strata, with 2-tailed <italic>P</italic> values &lt;.05 considered statistically significant.<sup><xref rid="ioi200046r30" ref-type="bibr">30</xref></sup> Statistical analysis was conducted using R, version 3.1.1 (R Project for Statistical Computing).</p>
              </sec>
            </sec>
            <sec id="H1-3-IOI200046">
              <title>Results</title>
              <sec id="H2-3-IOI200046">
                <title>Trial Participants</title>
                <p>A total of 362 participants were randomized to either individual PFMT (n = 184) or group-based PFMT (n = 178). Among those, 165 of 184 women (90%) of the individual and 154 of 178 women (87%) of the group-based PFMT completed the 1-year follow-up and were included in the per-protocol analysis (<xref ref-type="fig" rid="ioi200046f1">Figure 1</xref>). The 43 participants who discontinued the study were included only in the ITT analyses. Those who dropped out had generally similar clinical and demographic characteristics to those who completed the trial, except for the completers being older (mean [SD], 68.2 [5.9] vs 65.8 [4.3] years; <italic>P</italic> = .002) (eTable 3 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>).</p>
                <fig id="ioi200046f1" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Consolidated Standards of Reporting Trials (CONSORT) Diagram</title>
                  </caption>
                  <graphic xlink:href="jamainternmed-e202993-g001"/>
                </fig>
                <p>At baseline, no imbalances in any potential confounders were found between intervention arms (<xref rid="ioi200046t1" ref-type="table">Table 1</xref>). The attendance to the 12 PFMT sessions was, on average, 98% (mean [SD], 11.7 [0.6] sessions) for individual and 95% (mean [SD], 11.4 [1.0] sessions) for group-based PFMT. Only 7% (12 of 166) of group-based participants who completed the intervention requested a 20-minute session with their physiotherapists to confirm PFM contraction. Home PFM exercises were performed 4 to 5 times per week by 89% (152 of 171) of the individual and 86% (142 of 166) of the group-based PFMT participants during the 12-week intervention period. Thereafter, PFM exercises were performed at least once per week by 67% (110 of 165) the individual and 69% (107 of 154) of the group-based PFMT participants who completed the 1-year follow-up.</p>
                <table-wrap id="ioi200046t1" orientation="portrait" position="float">
                  <label>Table 1. </label>
                  <caption>
                    <title>Baseline Characteristics of the Intention-to-Treat Population</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="47.15%" span="1"/>
                    <col width="27.62%" span="1"/>
                    <col width="25.23%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Physiotherapy<xref ref-type="table-fn" rid="ioi200046t1n1"><sup>a</sup></xref></th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Individual (n = 184)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Group (n = 178)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67.9 (5.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">68.0 (5.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27.2 (4.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27.0 (4.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Parity, median (IQR)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1-2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1-3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cesarean section, median (IQR)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vaginal delivery, median (IQR)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0-2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0.75-3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Type of incontinence, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Stress </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (15)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">35 (20)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mixed </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">157 (85)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">143 (80)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Duration of symptoms, mean (SD), y<xref ref-type="table-fn" rid="ioi200046t1n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10.3 (10.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.2 (9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">No. of comorbidities<xref ref-type="table-fn" rid="ioi200046t1n3"><sup>c</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="ioi200046t1n4"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.4 (2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.5 (2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. of medications, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.2 (2.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.9 (2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">MMSE<xref ref-type="table-fn" rid="ioi200046t1n5"><sup>e</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29.0 (1.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29.1 (1.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Previous surgery for incontinence, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Current smoker, No. (%)<xref ref-type="table-fn" rid="ioi200046t1n6"><sup>f</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: BMI, body-mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range; MMSE, Mini-Mental State Examination.</p>
                    <fn id="ioi200046t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>None of the between-group comparisons was significant at baseline.</p>
                    </fn>
                    <fn id="ioi200046t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Data available on 181 participants in the individual cohort and 175 patients in the group cohort.</p>
                    </fn>
                    <fn id="ioi200046t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Data available on 176 participants in the group cohort.</p>
                    </fn>
                    <fn id="ioi200046t1n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Number of comorbidities per participant as reported from a standardized list of 28 diseases and conditions: high blood pressure, osteoporosis, hypercholesterolemia, heart disease, stroke, lung disease/asthma, tuberculosis, depression, loss of vision, vascular diseases, renal failure, glaucoma, transplant, gout, fractured hip, breast cancer, rheumatoid arthritis, other arthritis (ie, osteoarthritis), diabetes, deterioration in hearing, epilepsy, migraines, Parkinson disease, HIV, hepatic impairment, stomach ulcers, thyroid disease, and colitis.</p>
                    </fn>
                    <fn id="ioi200046t1n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>Scores range from 0 to 30, with lower scores (≤17) indicating severe cognitive impairment and higher scores (≥24) indicating no cognitive impairment.</p>
                    </fn>
                    <fn id="ioi200046t1n6">
                      <label>
                        <sup>f</sup>
                      </label>
                      <p>Data available on 183 participants in the individual cohort.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-4-IOI200046">
                <title>Primary Outcome</title>
                <p><xref ref-type="fig" rid="ioi200046f2">Figure 2</xref>A illustrates the reduction in leakage episode frequency at 12 weeks and 1 year, relative to baseline (<italic>P</italic> &lt; .001 for both intervention arms at both time points). At 1 year, the median percentage reduction in urinary incontinence episodes in the individual intervention was 70% (95% CI, 44%-89%) vs 74% (95% CI, 46%-86%) in the group-based intervention (difference, −4%; 95% CI, −10% to 7%; <italic>P</italic> = .58). In the ITT sensitivity analysis, the median percentage reduction in the number of urinary incontinence episodes in the individual intervention was 67% (95% CI, 25%-88%) vs 69% (95% CI, 31%-86%) in the group-based intervention (difference, −2%; 95% CI, −12% to 5%; <italic>P</italic> = .58). In both of these analyses, the upper boundary of the 95% CI for the difference in percentage reduction in urinary incontinence episodes at 1 year was lower than the prespecified margin for noninferiority of 10% (<xref ref-type="fig" rid="ioi200046f2">Figure 2</xref>B). Comparison of the mean reductions confirmed a lack of difference with somewhat wider 95% CIs owing to highly nonnormal distributions (per protocol difference, −1%; 95% CI, −13% to 12%; <italic>P</italic> = .54) (eTable 4 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>).</p>
                <fig id="ioi200046f2" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Primary Outcome by Pelvic Floor Muscle Training (PFMT) Treatment Group</title>
                    <p>A, Median frequency and interquartile range (IQR) of leakage episodes at baseline, 3 months, and 12 months following randomization. B, Leakage reduction at 1 year relative to baseline, both per protocol and for the intention to treat (ITT) analysis. In both cases the upper boundary of the 95% CI for the difference in percentage reduction in leakage episodes at 1 year was less than the prespecified margin for noninferiority of 10%.</p>
                  </caption>
                  <graphic xlink:href="jamainternmed-e202993-g002"/>
                </fig>
              </sec>
              <sec id="H2-5-IOI200046">
                <title>Secondary Outcomes</title>
                <p><xref rid="ioi200046t2" ref-type="table">Table 2</xref> summarizes secondary outcome results related to urinary incontinence. Both of the study arms showed statistically significant improvement for all outcomes relative to baseline. For example, the leakage episodes per day went from a median of 1.6 (interquartile range, 0.9 to 2.7) at baseline to 0.4 (interquartile range, 0.1 to 1.0) at 1 year; <italic>P</italic>&lt;.001 for individual and from 1.4 (interquartile range, 0.9 to 2.1) at baseline to 0.4 (interquartile range, 0.1 to 1.0) at 1 year; <italic>P</italic>&lt;.001 for group-based PFMT). Except for slightly more severe symptoms in the group-based arm immediately after treatment (statistically but not clinically significant difference in median ICIQ-Urinary Incontinence Short Form scores), there were no significant differences between the 2 treatment arms for signs, symptoms, or urinary incontinence–specific QoL outcomes (<xref rid="ioi200046t2" ref-type="table">Table 2</xref>). ITT sensitivity analysis confirmed these results (<xref rid="ioi200046t2" ref-type="table">Table 2</xref>). Comparisons of the mean values of urinary incontinence–related secondary outcomes showed similar results (eTable 4 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>). Moreover, at the 1-year follow-up, a high and almost identical proportion of women in each study arm reported feeling much better or very much better on the Patient Global Impression of Improvement (138 of 163 [85%] vs 132 of 153 [86%]; difference, −1%; 95% CI, −9% to 7%; <italic>P</italic> = .88). Satisfaction with treatment (does not need other treatment) was reported by 148 of 164 (90%) individual vs 139 of 153 (91%) group-based PFMT participants (difference, −1%; 95% CI, −7% to 5%; <italic>P</italic> &gt; .99).</p>
                <table-wrap id="ioi200046t2" orientation="portrait" position="float">
                  <?xpp 2col?>
                  <label>Table 2. </label>
                  <caption>
                    <title>Urinary Incontinence-Specific Secondary Outcomes at 12-Week and 1-Year Follow-up</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="17.75%" span="1"/>
                    <col width="15.7%" span="1"/>
                    <col width="21.14%" span="1"/>
                    <col width="19.16%" span="1"/>
                    <col width="17.74%" span="1"/>
                    <col width="8.51%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Variable</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Total participants (individual/group), No.</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Median (IQR)</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Median difference (95% CI)</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Individual PFMT</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Group PFMT</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="6" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Leakage episodes/d</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">360 (183/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.57 (0.86 to 2.71)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.43 (0.86 to 2.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">336 (171/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.14 to 1.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.14 to 1.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (−0.14 to 0.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.20</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">318 (165/153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.10 to 1.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.14 to 1.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (−0.29 to 0.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.67</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">360 (183/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.14 to 1.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.14 to 1.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (−0.29 to 0.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.57</td>
                      </tr>
                      <tr>
                        <td colspan="6" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Urine loss on pad test, g per 24 h</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">351 (180/171)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.67 (2.42 to 16.05)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5.71 (2.52 to 17.66)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">319 (166/153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.4 (1.16 to 5.82)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.52 (1.51 to 5.15)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−0.12 (−0.81 to 0.81)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.49</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">273 (142/131)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.75 (1.19 to 6.26)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.11 (1.10 to 4.86)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.64 (−0.14 to 1.42)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.92</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">358 (183/175)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.97 (1.29 to 7.07)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.43 (1.24 to 5.59)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.54 (−0.22 to 1.38)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.85</td>
                      </tr>
                      <tr>
                        <td colspan="6" valign="top" align="left" scope="col" rowspan="1">
                          <bold>ICIQ-UI SF</bold>
                          <xref ref-type="table-fn" rid="ioi200046t2n1">
                            <sup>
                              <bold>a</bold>
                            </sup>
                          </xref>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">361 (184/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12.50 (10.00 to 14.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12.00 (10.00 to 15.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">335 (171/164)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.00 (4.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.00 (4.75 to 10.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−1 (−2 to 0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.02</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">314 (162/152)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.00 (5.00 to 10.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.00 (4.00 to 10.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (−1 to 2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.87</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">362 (184/178)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.00 (5.00 to 11.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.00 (4.00 to 11.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (−0.5 to 2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.85</td>
                      </tr>
                      <tr>
                        <td colspan="6" valign="top" align="left" scope="col" rowspan="1">
                          <bold>ICIQ-LUTS QoL</bold>
                          <xref ref-type="table-fn" rid="ioi200046t2n2">
                            <sup>
                              <bold>b</bold>
                            </sup>
                          </xref>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">358 (182/176)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32.00 (28.00 to 38.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32.00 (27.00 to 41.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">336 (171/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24.00 (21.00 to 26.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24.00 (21.00 to 27.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (−2 to 1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.39</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">314 (163/151)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23.00 (21.00 to 27.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23.00 (21.00 to 27.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (−1 to 1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.51</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">361 (184/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24.00 (21.00 to 27.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23.00 (21.00 to 29.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (−1 to 1.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.52</td>
                      </tr>
                      <tr>
                        <td colspan="6" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Perceived benefit on PGI-I, No. (%)</bold>
                          <xref ref-type="table-fn" rid="ioi200046t2n3">
                            <sup>
                              <bold>c</bold>
                            </sup>
                          </xref>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">337 (171/166)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">164 (96)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">160 (96)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (−4 to 4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">316 (163/153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">138 (85)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">132 (86)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−1 (−9 to 7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.88</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">337 (171/166)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">146 (85)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">144 (87)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−2 (−9 to 5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.91</td>
                      </tr>
                      <tr>
                        <td colspan="6" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Satisfaction, No. (%)</bold>
                          <xref ref-type="table-fn" rid="ioi200046t2n4">
                            <sup>
                              <bold>d</bold>
                            </sup>
                          </xref>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">336 (171/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">160 (94)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">150 (91)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (−3 to 9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.48</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">317 (164/153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">148 (90)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">139 (91)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−1 (−7 to 5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">336 (171/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">154 (90)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">150 (91)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−1 (−7 to 5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.94</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: ICIQ-UI SF, International Consultation on Incontinence Modular Questionnaire-Urinary Incontinence Short Form; ICIQ-LUTS QoL, International Consultation on Incontinence Modular Questionnaire-Lower Urinary Tract Symptoms Quality of Life; IQR, interquartile range; ITT, intention-to-treat; NA, not applicable; PFMT, pelvic floor muscle training; PGI-I, Patient Global Impression of Improvement.</p>
                    <fn id="ioi200046t2n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Score range, 0 to 21; greater values indicate increased severity (minimal clinically important difference, 2.52 points).<sup><xref rid="ioi200046r27" ref-type="bibr">27</xref></sup></p>
                    </fn>
                    <fn id="ioi200046t2n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Score range, 19 to 76; greater values indicate a higher effect on quality of life (minimal clinically important difference, 3.71 points).<sup><xref rid="ioi200046r27" ref-type="bibr">27</xref></sup></p>
                    </fn>
                    <fn id="ioi200046t2n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Number of participants stating they are very much better or much better.</p>
                    </fn>
                    <fn id="ioi200046t2n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Number of participants stating they were satisfied (do not need another treatment) as opposed to unsatisfied (would like another treatment).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>For all secondary outcomes related to other lower urinary tract symptoms, there were no statistically significant differences between the 2 treatment arms at the 1-year follow-up in both per-protocol and ITT analysis in either the median (<xref rid="ioi200046t3" ref-type="table">Table 3</xref>) or the mean values (eTable 5 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>). Urinary frequency and nocturia (&gt;2 episodes per night) on the 7-day bladder diary and the ICIQ-Nocturia questionnaire showed statistically significant improvements relative to baseline at both time points in each of the 2 arms. Urinary frequency per day went from a median of 8.3 (IQR, 6.3-10.1) micturitions at baseline to 7.4 (6.1-8.7) (<italic>P</italic> &lt; .005) at 1 year for individual and from 8.5 (IQR, 6.9-10.1) at baseline to 7.0 (IQR, 5.9-8.4) (<italic>P</italic> &lt; .005) at 1 year for group-based PFMT. The number of participants with nocturia (&gt;2 episodes per night) went from 59 participants (32%) at baseline to 36 participants (22%) (<italic>P</italic> = .04) at 1 year for individual and from 68 (38%) at baseline to 38 (25%) (<italic>P</italic> &lt; .005) at 1 year for group-based PFMT. All 3 ICIQ-Vaginal Symptoms subscales (vaginal symptoms, sexual matter, and vaginal symptoms effect on QoL) were significantly improved at both time points. For example, vaginal symptoms subscale on the ICIQ-VS went from a median of 4.0 (IQR, 0.0- 9.5) at baseline to 2.0 (IQR, 0.0-5.5) (<italic>P</italic> &lt; .005) at 1 year for individual and from 4.0 (IQR, 1.0-10.0) at baseline to 0.5 (IQR, 0.0-4.3) (<italic>P</italic> &lt; .005) at 1 year for group-based PFMT. The participants’ confidence in their ability to prevent urine loss according to the Geriatric Self-Efficacy Index also improved: the total score went from a median of 55 (IQR, 41-69) at baseline to 89 (IQR, 70-102) (<italic>P</italic> &lt; .005) at 1 year for individual PFMT and from 59 (IQR, 44-73) at baseline to 93 (IQR, 76- 107) (<italic>P</italic> &lt; .005) at 1 year for group-based PFMT. However, findings on sexual issues associated with lower urinary tract symptoms as determined by the ICIQ-Female Lower Urinary Tract Symptoms Sex did not change significantly at any time.</p>
                <table-wrap id="ioi200046t3" orientation="portrait" position="float">
                  <?xpp 2col?>
                  <label>Table 3. </label>
                  <caption>
                    <title>Further Secondary Outcomes at 12-Week and 1-Year Follow-up</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="27.36%" span="1"/>
                    <col width="14.3%" span="1"/>
                    <col width="17.47%" span="1"/>
                    <col width="17.47%" span="1"/>
                    <col width="16.16%" span="1"/>
                    <col width="7.11%" span="1"/>
                    <col width="0.13%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Variable</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Total participants (individual/group), No.</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Median (IQR)</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Median difference (95% CI)</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Individual PFMT</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Group PFMT</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="7" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Other lower urinary tract symptoms</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Micturition, 7-d bladder diary</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">359 (183/176)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.29 (6.29 to 10.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.5 (6.86 to 10.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">336 (171/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.86 (5.57 to 8.29)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.57 (5.57 to 8.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.29 (−0.43 to 0.71)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.63</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">318 (165/153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.43 (6.14 to 8.71)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.00 (5.86 to 8.43)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (−0.14 to 0.86)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.88</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">360 (183/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.29 (6.07 to 8.64)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.00 (5.71 to 8.43)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.29 (−0.14 to 0.86)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.86</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Nocturia, &gt;2 episodes per night, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">362 (184/178)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">59 (32)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">68 (38)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">337 (171/166)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29 (17)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">35 (21)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−4.00 (−12.00 to 4.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.57</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">317 (164/153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">36 (22)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 (25)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−3.00 (−12.00 to 6.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.24</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">361 (184/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 (21)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">46 (26)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−5.00 (−14.00 to 4.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.12</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICIQ-N<xref ref-type="table-fn" rid="ioi200046t3n1"><sup>a</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">361 (184/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (1.00 to 4.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.00 (2.00 to 4.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">336 (170/166)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.00 (1.00 to 2.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.00 (1.00 to 2.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−1.00 to 1.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.13</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">317 (164/153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (1.00 to 3.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (1.00 to 2.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−1.00 to 1.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.40</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">362 (184/178)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (1.00 to 3.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (1.00 to 3.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−1.00 to 0.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.25</td>
                      </tr>
                      <tr>
                        <td colspan="7" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Vaginal and sexual symptoms</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICIQ-VS vaginal symptoms subscale<xref ref-type="table-fn" rid="ioi200046t3n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">358 (183/175)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.00 (0.00 to 9.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.00 (1.00 to 10.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">335 (170/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.00 to 6.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.00 to 6.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−1.00 to 2.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.77</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">315 (163/152)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.00 to 5.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.50 (0.00 to 4.25)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.50 (0.00-3.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.89</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">362 (184/178)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.00 to 6.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.00 to 6.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−1.50 to 2.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.67</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICIQ-VS sexual matters subscale<xref ref-type="table-fn" rid="ioi200046t3n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">127 (70/57)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 25.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 36.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">120 (63/57)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 5.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 28.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−9.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.05</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">103 (58/45)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 10.25)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00-4.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.81</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">160 (87/73)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 13.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 24.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−3.00 to 1.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.39</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICIQ-VS quality of life subscale<xref ref-type="table-fn" rid="ioi200046t3n4"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">361 (184/177)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 3.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 4.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">334 (169/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.46</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">314 (163/151)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.80</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">362 (184/178)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.47</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICIQ-FLUTS<xref ref-type="table-fn" rid="ioi200046t3n5"><sup>e</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">347 (176/171)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (2.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (3.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">325 (161/164)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (1.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (1.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (−3.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.46</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">309 (161/148)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (1.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (2.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.14</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">360 (184/176)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (1.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.00 (2.00 to 8.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.00 to 0.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.20</td>
                      </tr>
                      <tr>
                        <td colspan="7" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Self-efficacy</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Geriatric self-efficacy index<xref ref-type="table-fn" rid="ioi200046t3n6"><sup>f</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">362 (184/178)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55.00 (41.00 to 69.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">59.00 (44.25 to 73.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After 12-wk treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">335 (170/165)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">92.00 (79.00 to 104.75)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">95.00 (80.00 to 107.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−3.00 (−8.00 to 3.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.80</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">309 (159/150)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">89.00 (70.00 to 102.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">93.00 (76.25 to 107.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−4.00 (−12.50 to 2.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.98</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 1-y follow-up (ITT)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">362 (184/178)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">86.50 (69.00 to 102.00)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">92.00 (74.00 to 106.75)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">−5.50 (−12.50 to 1.50)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.95</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: ICIQ, International Consultation on Incontinence Questionnaire; ICIQ-FLUTS, ICIQ-Female Lower Urinary Tract Symptoms Associated With Sexual Matters; ICIQ-N, ICIQ-Nocturia; ICIQ-VS, ICIQ-Vaginal Symptoms; IQR, interquartile range; ITT, intention to treat; LUT, lower urinary tract; PFMT, pelvic floor muscle training.</p>
                    <fn id="ioi200046t3n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Score range, 0 to 8; higher values indicate increased symptom severity.</p>
                    </fn>
                    <fn id="ioi200046t3n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Score range, 0 to 53; higher values indicate increased symptom severity.</p>
                    </fn>
                    <fn id="ioi200046t3n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Score range, 0 to 58; higher values indicate increased symptom severity.</p>
                    </fn>
                    <fn id="ioi200046t3n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Score range, 0 to 10; higher values indicate increased symptom severity.</p>
                    </fn>
                    <fn id="ioi200046t3n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>Score range, 0 to 14; higher values indicate increased symptom severity.</p>
                    </fn>
                    <fn id="ioi200046t3n6">
                      <label>
                        <sup>f</sup>
                      </label>
                      <p>Score range, 0 to 120; higher values indicate higher self-efficacy.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>A high and almost identical proportion of women reached the minimal clinically important difference for leakage episodes, urinary incontinence severity, and urinary incontinence–specific QoL at the 1-year follow-up in the 2 arms (eTable 8 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>). In addition, multivariable logistic analyses of the 1-year primary dichotomized outcome (percentage of urinary incontinence reduction &lt;50% or ≥50%) showed that, after Bonferroni correction owing to multiple interactions to test, there were no statistically significant interactions between the intervention and any of the a priori identified potential effect modifiers (study center, urinary incontinence type, urinary incontinence severity, age, and BMI) (eTable 6 and eTable 7 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>). These results confirmed that the association between the intervention arms (group-based and individual PFMT) and the binary outcome was similar across different subgroups.</p>
              </sec>
              <sec id="H2-6-IOI200046">
                <title>Adverse Events</title>
                <p>Throughout the trial, no serious adverse events were reported in either study arm. Minor adverse events were reported by 27 women in the individual PFMT arm, including vaginal spotting (6 women) or vaginal discomfort while using intravaginal biofeedback (21 women). Five women in the group-based PFMT arm reported vaginal discomfort. These reported adverse events occurred primarily in the first 2 sessions and resolved without the need for treatment.</p>
                <p>Although the participants were asked to refrain from seeking other forms of treatment specific to their urinary incontinence condition during the study period, 5 of 165 women (3%) in the individual PFMT arm vs 7 of 154 women (5%) in the group-based PFMT arm reported having visited health professionals, taken medication, or pursued other treatments at the 1-year follow-up. Details are given in eTable 9 in <xref ref-type="supplementary-material" rid="note-IOI200046-1-s">Supplement 2</xref>.</p>
              </sec>
            </sec>
            <sec id="H1-4-IOI200046">
              <title>Discussion</title>
              <p>To our knowledge, this is the first and only adequately powered trial to assess noninferiority of group-based PFMT compared with individual PFMT for urinary incontinence. In both per-protocol and ITT analyses, group-based PFMT was not inferior to the standard individual PFMT for the treatment of stress or mixed urinary incontinence in older women. These results provide controlled evidence that confirms earlier inconclusive findings from 6 smaller randomized clinical trials in younger women. Many of these trials had significant risk of bias, no long-term follow-up, and were not sufficiently powered or designed to assess noninferiority.<sup><xref rid="ioi200046r31" ref-type="bibr">31</xref>,<xref rid="ioi200046r32" ref-type="bibr">32</xref>,<xref rid="ioi200046r33" ref-type="bibr">33</xref>,<xref rid="ioi200046r34" ref-type="bibr">34</xref>,<xref rid="ioi200046r35" ref-type="bibr">35</xref>,<xref rid="ioi200046r36" ref-type="bibr">36</xref>,<xref rid="ioi200046r37" ref-type="bibr">37</xref></sup></p>
              <p>Our study demonstrated a median percentage reduction in urinary incontinence episodes at 1 year of 70% in individual PFMT compared with a 74% reduction in group-based PFMT, which did not vary with study center, urinary incontinence type, urinary incontinence severity, age, and BMI. Furthermore, these findings indicate equal or greater urinary incontinence reduction compared with previous studies assessing the effect of individual physiotherapy in a similar population.<sup><xref rid="ioi200046r8" ref-type="bibr">8</xref>,<xref rid="ioi200046r24" ref-type="bibr">24</xref>,<xref rid="ioi200046r38" ref-type="bibr">38</xref></sup> Individual and group-based PFMT had similar effectiveness for all secondary outcomes except sexual issues associated with lower urinary tract symptoms at 1 year. Adherence to treatment sessions and home exercises was high and loss to follow-up was low, indicating acceptability of both interventions. Few participants had adverse events; all were minor, reversible, and occurred primarily in the early stage of each intervention.</p>
              <sec id="H2-7-IOI200046">
                <title>Limitations and Strengths</title>
                <p>This study’s exclusion criteria and intensive intervention could limit generalizability of the results to either frail older or younger women who may not be able to participate in or adhere to this intensive intervention. From a clinical and health service perspective, strengths of our findings indicate that the group-based approach makes it possible to rapidly increase the number of women treated with PFMT. Making conservative management more accessible may help delay or reduce the need for urinary incontinence surgery and reduce the burden of urinary incontinence on the health care system. Overall, our results demonstrate that older women with stress or mixed urinary incontinence will attend, adhere, and gain clinically important benefits from group-based PFMT.</p>
              </sec>
            </sec>
            <sec id="H1-5-IOI200046">
              <title>Conclusions</title>
              <p>In a multicenter noninferiority trial, group-based PFMT was shown to be noninferior to the standard individual PFMT at 1 year postrandomization for the treatment of stress and mixed urinary incontinence in older women. Widespread use of this effective intervention could positively affect continence-care affordability and treatment availability.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-IOI200046">
              <title>References</title>
              <ref id="ioi200046r1">
                <label>1</label>
                <mixed-citation publication-type="book"><person-group><name name-style="western"><surname>Milsom</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cartwright</surname><given-names>R</given-names></name>, <etal/></person-group><chapter-title>Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal Incontinence (AI).</chapter-title> In: <person-group><name name-style="western"><surname>Abrams</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cardozo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wagg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wein</surname><given-names>A</given-names></name></person-group>, eds. <source>Incontinence.</source>
<edition>6th ed.</edition>
<publisher-loc>Bristol, UK</publisher-loc>: <publisher-name>ICI-ICS International Continence Society</publisher-name>; <year>2017</year>:<fpage>1</fpage>-<lpage>141</lpage>.</mixed-citation>
              </ref>
              <ref id="ioi200046r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Hannestad</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Rortveit</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sandvik</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hunskaar</surname><given-names>S</given-names></name>; <collab>Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag</collab></person-group><article-title>A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag</article-title>. <source>J Clin Epidemiol</source>. <year>2000</year>;<volume>53</volume>(<issue>11</issue>):<fpage>1150</fpage>-<lpage>1157</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0895-4356(00)00232-8</pub-id><?supplied-pmid 11106889?><pub-id pub-id-type="pmid">11106889</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Johnson</surname><given-names>TM</given-names><suffix>II</suffix></name>, <name name-style="western"><surname>Kincade</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bernard</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Busby-Whitehead</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hertz-Picciotto</surname><given-names>I</given-names></name>, <name name-style="western"><surname>DeFriese</surname><given-names>GH</given-names></name></person-group><article-title>The association of urinary incontinence with poor self-rated health</article-title>. <source>J Am Geriatr Soc</source>. <year>1998</year>;<volume>46</volume>(<issue>6</issue>):<fpage>693</fpage>-<lpage>699</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.1998.tb03802.x</pub-id><?supplied-pmid 9625183?><pub-id pub-id-type="pmid">9625183</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Hunskaar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vinsnes</surname><given-names>A</given-names></name></person-group><article-title>The quality of life in women with urinary incontinence as measured by the sickness impact profile</article-title>. <source>J Am Geriatr Soc</source>. <year>1991</year>;<volume>39</volume>(<issue>4</issue>):<fpage>378</fpage>-<lpage>382</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.1991.tb02903.x</pub-id><?supplied-pmid 2010587?><pub-id pub-id-type="pmid">2010587</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Ko</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>S-J</given-names></name>, <name name-style="western"><surname>Salmon</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Bron</surname><given-names>MS</given-names></name></person-group><article-title>The impact of urinary incontinence on quality of life of the elderly</article-title>. <source>Am J Manag Care</source>. <year>2005</year>;<volume>11</volume>(<issue>4</issue>)(<supplement>suppl</supplement>):<fpage>S103</fpage>-<lpage>S111</lpage>.<?supplied-pmid 16161383?><pub-id pub-id-type="pmid">16161383</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Sen</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Onaran</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aksakal</surname><given-names>N</given-names></name>, <etal/></person-group><article-title>The impact of urinary incontinence on female sexual function</article-title>. <source>Adv Ther</source>. <year>2006</year>;<volume>23</volume>(<issue>6</issue>):<fpage>999</fpage>-<lpage>1008</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF02850220</pub-id><?supplied-pmid 17276967?><pub-id pub-id-type="pmid">17276967</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Dumoulin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cacciari</surname><given-names>LP</given-names></name>, <name name-style="western"><surname>Hay-Smith</surname><given-names>EJC</given-names></name></person-group><article-title>Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>10</volume>(<issue>10</issue>):<elocation-id>CD005654</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD005654.pub4</pub-id><?supplied-pmid 30288727?><pub-id pub-id-type="pmid">30288727</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r8">
                <label>8</label>
                <mixed-citation publication-type="book"><person-group><name name-style="western"><surname>Dumoulin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Adewuyi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Booth</surname><given-names>J</given-names></name>, <etal/></person-group><chapter-title>Adult conservative management.</chapter-title> In: <person-group><name name-style="western"><surname>Abrams</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cardozo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wagg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wein</surname><given-names>A</given-names></name></person-group>, eds. <source>Incontinence.</source>
<edition>6th ed.</edition>
<publisher-loc>Bristol, UK</publisher-loc>: <publisher-name>ICI-ICS International Continence Society</publisher-name>; <year>2017</year>:<fpage>1443</fpage>-<lpage>1628</lpage>.</mixed-citation>
              </ref>
              <ref id="ioi200046r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Syan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Brucker</surname><given-names>BM</given-names></name></person-group><article-title>Guideline of guidelines: urinary incontinence</article-title>. <source>BJU Int</source>. <year>2016</year>;<volume>117</volume>(<issue>1</issue>):<fpage>20</fpage>-<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bju.13187</pub-id><?supplied-pmid 26033093?><pub-id pub-id-type="pmid">26033093</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Bland</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Dugan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>SJ</given-names></name>, <etal/></person-group><article-title>The effects of implementation of the Agency for Health Care Policy and Research urinary incontinence guidelines in primary care practices</article-title>. <source>J Am Geriatr Soc</source>. <year>2003</year>;<volume>51</volume>(<issue>7</issue>):<fpage>979</fpage>-<lpage>984</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2389.2003.51311.x</pub-id><?supplied-pmid 12834518?><pub-id pub-id-type="pmid">12834518</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Engen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Svenningsen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Schiøtz</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Kulseng-Hanssen</surname><given-names>S</given-names></name></person-group><article-title>Mid-urethral slings in young, middle-aged, and older women</article-title>. <source>Neurourol Urodyn</source>. <year>2018</year>;<volume>37</volume>(<issue>8</issue>):<fpage>2578</fpage>-<lpage>2585</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nau.23583</pub-id><?supplied-pmid 30178571?><pub-id pub-id-type="pmid">30178571</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Cook</surname><given-names>T.</given-names></name></person-group><article-title>Group treatment of female urinary incontinence</article-title>. <source>Physiotherapy.</source><year>2001</year>;<volume>87</volume>(<issue>5</issue>):<fpage>226</fpage>-<lpage>234</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0031-9406(05)60783-3</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Dumoulin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Morin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mayrand</surname><given-names>M-H</given-names></name>, <name name-style="western"><surname>Tousignant</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Abrahamowicz</surname><given-names>M</given-names></name></person-group><article-title>Group physiotherapy compared to individual physiotherapy to treat urinary incontinence in aging women: study protocol for a randomized controlled trial</article-title>. <source>Trials</source>. <year>2017</year>;<volume>18</volume>(<issue>1</issue>):<fpage>544</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13063-017-2261-4</pub-id><?supplied-pmid 29145873?><pub-id pub-id-type="pmid">29145873</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Burgio</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Goode</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Locher</surname><given-names>JL</given-names></name>, <etal/></person-group><article-title>Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>288</volume>(<issue>18</issue>):<fpage>2293</fpage>-<lpage>2299</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.288.18.2293</pub-id><?supplied-pmid 12425706?><pub-id pub-id-type="pmid">12425706</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Bradley</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Rahn</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Nygaard</surname><given-names>IE</given-names></name>, <etal/></person-group><article-title>The questionnaire for urinary incontinence diagnosis (QUID): validity and responsiveness to change in women undergoing non-surgical therapies for treatment of stress predominant urinary incontinence</article-title>. <source>Neurourol Urodyn</source>. <year>2010</year>;<volume>29</volume>(<issue>5</issue>):<fpage>727</fpage>-<lpage>734</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nau.20818</pub-id><?supplied-pmid 19787711?><pub-id pub-id-type="pmid">19787711</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Longstreth</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>Chey</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Houghton</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Mearin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Spiller</surname><given-names>RC</given-names></name></person-group><article-title>Functional bowel disorders</article-title>. <source>Gastroenterology</source>. <year>2006</year>;<volume>130</volume>(<issue>5</issue>):<fpage>1480</fpage>-<lpage>1491</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.gastro.2005.11.061</pub-id><?supplied-pmid 16678561?><pub-id pub-id-type="pmid">16678561</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Haylen</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Maher</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Barber</surname><given-names>MD</given-names></name>, <etal/></person-group><article-title>An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP)</article-title>. <source>Neurourol Urodyn</source>. <year>2016</year>;<volume>35</volume>(<issue>2</issue>):<fpage>137</fpage>-<lpage>168</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nau.22922</pub-id><?supplied-pmid 26749391?><pub-id pub-id-type="pmid">26749391</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Locher</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Goode</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Worrell</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Burgio</surname><given-names>KL</given-names></name></person-group><article-title>Reliability assessment of the bladder diary for urinary incontinence in older women</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2001</year>;<volume>56</volume>(<issue>1</issue>):<fpage>M32</fpage>-<lpage>M35</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/56.1.M32</pub-id><?supplied-pmid 11193230?><pub-id pub-id-type="pmid">11193230</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Karantanis</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Stevermuer</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Simons</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>O’Sullivan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>KH</given-names></name></person-group><article-title>The repeatability of the 24-hour pad test</article-title>. <source>Int Urogynecol J Pelvic Floor Dysfunct</source>. <year>2005</year>;<volume>16</volume>(<issue>1</issue>):<fpage>63</fpage>-<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00192-004-1199-8</pub-id><?supplied-pmid 15647965?><pub-id pub-id-type="pmid">15647965</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Avery</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Donovan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gotoh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Abrams</surname><given-names>P</given-names></name></person-group><article-title>ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence</article-title>. <source>Neurourol Urodyn</source>. <year>2004</year>;<volume>23</volume>(<issue>4</issue>):<fpage>322</fpage>-<lpage>330</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nau.20041</pub-id><?supplied-pmid 15227649?><pub-id pub-id-type="pmid">15227649</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kelleher</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Cardozo</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Khullar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Salvatore</surname><given-names>S</given-names></name></person-group><article-title>A new questionnaire to assess the quality of life of urinary incontinent women</article-title>. <source>Br J Obstet Gynaecol</source>. <year>1997</year>;<volume>104</volume>(<issue>12</issue>):<fpage>1374</fpage>-<lpage>1379</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1471-0528.1997.tb11006.x</pub-id><?supplied-pmid 9422015?><pub-id pub-id-type="pmid">9422015</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Tannenbaum</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Brouillette</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Michaud</surname><given-names>J</given-names></name>, <etal/></person-group><article-title>Responsiveness and clinical utility of the geriatric self-efficacy index for urinary incontinence</article-title>. <source>J Am Geriatr Soc</source>. <year>2009</year>;<volume>57</volume>(<issue>3</issue>):<fpage>470</fpage>-<lpage>475</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2008.02146.x</pub-id><?supplied-pmid 19187418?><pub-id pub-id-type="pmid">19187418</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Yalcin</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bump</surname><given-names>RC</given-names></name></person-group><article-title>Validation of two global impression questionnaires for incontinence</article-title>. <source>Am J Obstet Gynecol</source>. <year>2003</year>;<volume>189</volume>(<issue>1</issue>):<fpage>98</fpage>-<lpage>101</lpage>. doi:<pub-id pub-id-type="doi">10.1067/mob.2003.379</pub-id><?supplied-pmid 12861145?><pub-id pub-id-type="pmid">12861145</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Sherburn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carey</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bø</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Galea</surname><given-names>MP</given-names></name></person-group><article-title>Incontinence improves in older women after intensive pelvic floor muscle training: an assessor-blinded randomized controlled trial</article-title>. <source>Neurourol Urodyn</source>. <year>2011</year>;<volume>30</volume>(<issue>3</issue>):<fpage>317</fpage>-<lpage>324</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nau.20968</pub-id><?supplied-pmid 21284022?><pub-id pub-id-type="pmid">21284022</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Piaggio</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Elbourne</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Pocock</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>SJW</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name>; <collab>CONSORT Group</collab></person-group><article-title>Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>308</volume>(<issue>24</issue>):<fpage>2594</fpage>-<lpage>2604</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2012.87802</pub-id><?supplied-pmid 23268518?><pub-id pub-id-type="pmid">23268518</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Yalcin</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Viktrup</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bump</surname><given-names>RC</given-names></name></person-group><article-title>Reductions in stress urinary incontinence episodes: what is clinically important for women?</article-title><source>Neurourol Urodyn</source>. <year>2010</year>;<volume>29</volume>(<issue>3</issue>):<fpage>344</fpage>-<lpage>347</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nau.20744</pub-id><?supplied-pmid 19475576?><pub-id pub-id-type="pmid">19475576</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Nyström</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sjöström</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stenlund</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Samuelsson</surname><given-names>E</given-names></name></person-group><article-title>ICIQ symptom and quality of life instruments measure clinically relevant improvements in women with stress urinary incontinence</article-title>. <source>Neurourol Urodyn</source>. <year>2015</year>;<volume>34</volume>(<issue>8</issue>):<fpage>747</fpage>-<lpage>751</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nau.22657</pub-id><?supplied-pmid 25154378?><pub-id pub-id-type="pmid">25154378</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Goode</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Burgio</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Locher</surname><given-names>JL</given-names></name>, <etal/></person-group><article-title>Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>290</volume>(<issue>3</issue>):<fpage>345</fpage>-<lpage>352</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.290.3.345</pub-id><?supplied-pmid 12865375?><pub-id pub-id-type="pmid">12865375</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r29">
                <label>29</label>
                <mixed-citation publication-type="web">NCSS Statistical Software. <person-group><name name-style="western"><surname>Hintze</surname><given-names>J.</given-names></name></person-group> PASS <year>2008</year>
<ext-link ext-link-type="uri" xlink:href="http://www.ncss.com">http://www.ncss.com</ext-link>.</mixed-citation>
              </ref>
              <ref id="ioi200046r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Abrahamowicz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Beauchamp</surname><given-names>M-E</given-names></name>, <name name-style="western"><surname>Fournier</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dumont</surname><given-names>A</given-names></name></person-group><article-title>Evidence of subgroup-specific treatment effect in the absence of an overall effect: is there really a contradiction?</article-title><source>Pharmacoepidemiol Drug Saf</source>. <year>2013</year>;<volume>22</volume>(<issue>11</issue>):<fpage>1178</fpage>-<lpage>1188</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.3485</pub-id><?supplied-pmid 23939947?><pub-id pub-id-type="pmid">23939947</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Demain</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Hiller</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dziedzic</surname><given-names>K</given-names></name></person-group><article-title>Comparison of group and individual physiotherapy for female urinary incontinence in primary care</article-title>. <source>Physiotherapy.</source><year>2001</year>;<volume>87</volume>(<issue>5</issue>):<fpage>235</fpage>-<lpage>242</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0031-9406(05)60784-5</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Lamb</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Pepper</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lall</surname><given-names>R</given-names></name>, <etal/></person-group><article-title>Group treatments for sensitive health care problems: a randomised controlled trial of group versus individual physiotherapy sessions for female urinary incontinence</article-title>. <source>BMC Womens Health</source>. <year>2009</year>;<volume>9</volume>(<issue>1</issue>):<fpage>26</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1472-6874-9-26</pub-id><?supplied-pmid 19751517?><pub-id pub-id-type="pmid">19751517</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Janssen</surname><given-names>CCM</given-names></name>, <name name-style="western"><surname>Lagro-Janssen</surname><given-names>ALM</given-names></name>, <name name-style="western"><surname>Felling</surname><given-names>AJA</given-names></name></person-group><article-title>The effects of physiotherapy for female urinary incontinence: individual compared with group treatment</article-title>. <source>BJU Int</source>. <year>2001</year>;<volume>87</volume>(<issue>3</issue>):<fpage>201</fpage>-<lpage>206</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1464-410x.2001.02040.x</pub-id><?supplied-pmid 11167642?><pub-id pub-id-type="pmid">11167642</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>de Oliveira Camargo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rodrigues</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Arruda</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Ferreira Sartori</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Girão</surname><given-names>MJBC</given-names></name>, <name name-style="western"><surname>Castro</surname><given-names>RA</given-names></name></person-group><article-title>Pelvic floor muscle training in female stress urinary incontinence: comparison between group training and individual treatment using PERFECT assessment scheme</article-title>. <source>Int Urogynecol J Pelvic Floor Dysfunct</source>. <year>2009</year>;<volume>20</volume>(<issue>12</issue>):<fpage>1455</fpage>-<lpage>1462</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00192-009-0971-1</pub-id><?supplied-pmid 19690792?><pub-id pub-id-type="pmid">19690792</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Pereira</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>Correia</surname><given-names>GN</given-names></name>, <name name-style="western"><surname>Driusso</surname><given-names>P</given-names></name></person-group><article-title>Individual and group pelvic floor muscle training versus no treatment in female stress urinary incontinence: a randomized controlled pilot study</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>. <year>2011</year>;<volume>159</volume>(<issue>2</issue>):<fpage>465</fpage>-<lpage>471</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejogrb.2011.09.003</pub-id><?supplied-pmid 21962461?><pub-id pub-id-type="pmid">21962461</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Soni</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sonil</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Desai</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>H</given-names></name></person-group><article-title>Randomized controlled trial of group versus individual physiotherapy sessions for genuine stress incontinence in women</article-title>. <source>Indian J Physiother Occup Ther.</source><year>2013</year>;<volume>7</volume>(<issue>1</issue>):<fpage>110</fpage>-<lpage>115</lpage>.</mixed-citation>
              </ref>
              <ref id="ioi200046r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Paiva</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Ferla</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Darski</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Catarino</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Ramos</surname><given-names>JGL</given-names></name></person-group><article-title>Pelvic floor muscle training in groups versus individual or home treatment of women with urinary incontinence: systematic review and meta-analysis</article-title>. <source>Int Urogynecol J</source>. <year>2017</year>;<volume>28</volume>(<issue>3</issue>):<fpage>351</fpage>-<lpage>359</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00192-016-3133-2</pub-id><?supplied-pmid 27613622?><pub-id pub-id-type="pmid">27613622</pub-id></mixed-citation>
              </ref>
              <ref id="ioi200046r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name></person-group><article-title>The effects of multidimensional exercise treatment on community-dwelling elderly Japanese women with stress, urge, and mixed urinary incontinence: a randomized controlled trial</article-title>. <source>Int J Nurs Stud</source>. <year>2011</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1165</fpage>-<lpage>1172</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijnurstu.2011.02.016</pub-id><?supplied-pmid 21459381?><pub-id pub-id-type="pmid">21459381</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-IOI200046-1">
              <supplementary-material content-type="local-data" id="note-IOI200046-1-s">
                <label>Supplement 1.</label>
                <caption>
                  <p>Trial Protocol</p>
                </caption>
                <media xlink:href="jamainternmed-e202993-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>eTable 1. Consensus of Exercise Reporting Template (CERT)</p>
                  <p>eTable 2. Supervised Pelvic Floor Muscle Training Program</p>
                  <p>eTable 3. Baseline Characteristics of the Population That Completed the Study vs the Population That Did Not Complete the Study</p>
                  <p>eTable 4. Mean Values for the Primary and Urinary Incontinence Specific Secondary Outcomes in Individual and Group-Based Pelvic Floor Muscle Training at 12-Weeks and One-Year Follow-up</p>
                  <p>eTable 5. Mean Values for the Impact On Other Lower Urinary Tract Symptoms, Vaginal, Sexual Symptoms and Self-Efficacy in Individual and Group-Based Pelvic Floor Muscle Training at 12-Weeks and One-Year Follow-up</p>
                  <p>eTable 6. Primary Outcome- Percentage Reduction of Leakage Episodes in Individual and Group-Based Interventions at One-Year Follow-up According to Subgroups of Interest</p>
                  <p>eTable 7. Odds Ratios for the Association Between the Intervention Arm (Group-Based Pelvic Floor Muscle Training vs Individual Pelvic Floor Muscle Training) and the Binary Outcome of Percentage Reduction of Leakage Episodes</p>
                  <p>eTable 8. Minimal Clinically Important Differences at the One-Year Follow-up</p>
                  <p>eTable 9. Other Treatments Taken During the Study Period</p>
                  <p>eReferences</p>
                </caption>
                <media xlink:href="jamainternmed-e202993-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>Data Sharing Statement</p>
                </caption>
                <media xlink:href="jamainternmed-e202993-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
